LifeStance Health Group Inc · Q3 2022 earnings

Briefing

LifeStance reported a 25% increase in revenue, driven by a 24% net increase in total clinicians. The company is focused on organic growth, strategic infrastructure investments, and enhancing operating leverage and profitability.

LifeStance Health Group, Inc. announced its Q3 2022 financial results, with revenue reaching $217.6 million, a 25% increase compared to the previous year. The company reported a net loss of $37.9 million, which was impacted by stock-based compensation expenses. The company is shifting its focus to organic growth and profitability.

• Revenue increased by 25% to $217.6 million.
• Total clinicians increased by 24%, with a net addition of 205 clinicians in Q3.
• Net loss was $37.9 million, influenced by stock-based compensation expenses.
• Adjusted EBITDA was $15.4 million, a 44% increase.

Headline financials

Revenue & EPS history

LifeStance expects full year 2022 revenue of $845 to $850 million, Center Margin of $229 to $232 million, and Adjusted EBITDA of $50 to $53 million. For the fourth quarter of 2022, the company expects revenue of $215 million to $220 million, Center Margin of $55 million to $58 million, and Adjusted EBITDA of $7.5 million to $10.5 million.